BETA-CASEIN A2 AND PREVENTION OF INTESTINAL INFLAMMATION Russian patent published in 2022 - IPC A61K35/20 A61K38/17 A61P1/00 

FIELD: pharmaceutical industry.

SUBSTANCE: group of inventions relates to the pharmaceutical industry, namely to a method for prevention of chronic inflammation in a human by maintenance of the epigenetic status of one or more genes responsible for mediation of an inflammatory response. A method for prevention of chronic inflammation in a human by maintenance of the epigenetic status of one or more genes responsible for mediation of an inflammatory response is proposed, according to which the specified human consumes a dairy product, or the human is provided with a dairy product for consumption, where the specified dairy product contains beta-casein, while the specified beta-casein contains at least 50% by weight of beta-casein options containing proline at position 67 of a beta-casein amino acid sequence and contains less than 50% by weight of beta-casein options containing histidine at position 67 of the beta-casein amino acid sequence, while the specified one or more genes are selected from a group including MPO, IL1R, IL10, and NFKappaB. A dairy product for prevention of chronic inflammation in a human by maintenance of the epigenetic status of one or more genes responsible for mediation of an inflammatory response is proposed, while the specified dairy product contains beta-casein, where the specified beta-casein contains at least 50% by weight of beta-casein options containing proline at position 67 of the beta-casein amino acid sequence and contains less than 50% by weight of beta-casein options containing histidine at position 67 of the beta-casein amino acid sequence, while the specified one or more genes are selected from a group including MRO, IL1R, IL10, and NFKappaB. The use of milk for the production of a dairy product for prevention of chronic inflammation in a human by maintenance of the epigenetic status of one or more genes responsible for mediation of an inflammatory response is also proposed, while the specified milk contains beta-casein, where the specified beta-casein contains at least 50% by weight of beta-casein options containing proline at position 67 of the beta-casein amino acid sequence and contains less than 50% by weight of beta-casein options containing histidine at position 67 of the beta-casein amino acid sequence, while the specified one or more genes are selected from a group including MRO, IL1R, IL10, and NFKappaB.

EFFECT: above-described group of inventions contributes to the effective prevention of chronic inflammation in a human by maintenance of the epigenetic status of one or more genes responsible for mediation of an inflammatory response, which are selected from a group including MRO, IL1R, IL10, and NFKappaB.

17 cl, 9 dwg, 5 tbl, 10 ex